Capricor Therapeutics Newsroom

Capricor Therapeutics (NASDAQ:CAPR) Shareholder Returns Have Been Stellar, Earning 113% in 5 Years

Yahoo FinanceMay 22 11:19 ET

PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 09:58 ET

Express News | Capricor Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $14

ReutersMay 17 08:10 ET

Capricor Therapeutics Initiated at Outperform by Oppenheimer

Capricor Therapeutics Initiated at Outperform by Oppenheimer

Dow JonesMay 17 05:47 ET

Oppenheimer Initiates Coverage On Capricor Therapeutics With Outperform Rating, Announces Price Target of $14

Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics with a Outperform rating and announces Price Target of $14.

Analyst UpgradesMay 17 05:37 ET

Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments

TipRanksMay 15 14:15 ET

Expert Ratings For Capricor Therapeutics

During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent rat

BenzingaMay 14 15:01 ET

Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann

Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann

Dow JonesMay 14 14:32 ET

Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $24 to $25.

BenzingaMay 14 14:23 ET

Capricor Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald

Capricor Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald

Dow JonesMay 14 09:09 ET

Capricor Therapeutics | 10-Q: Quarterly report

SEC announcementMay 14 09:04 ET · Announcements

Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

BenzingaMay 14 07:31 ET

Capricor Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 684.31% HC Wainwright & Co. → $40 Reiterates Buy → Buy 04/25/2024 684.31% HC Wainwright & Co. →

BenzingaMay 14 07:30 ET

Analysts' Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)

TipRanksMay 14 07:20 ET

Capricor Therapeutics: A Strong Buy on Positive Financial Outlook and Regulatory Advancements

TipRanksMay 14 06:23 ET

Earnings Call Summary | Capricor Therapeutics(CAPR.US) Q1 2024 Earnings Conference

The following is a summary of the Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript:Financial Performance:Capricor Therapeutics reported a Q1 cash balance of around $39.9 million, up

moomoo AIMay 14 04:10 ET · Conference Call

Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Yahoo FinanceMay 14 03:04 ET

Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates

Yahoo FinanceMay 13 17:15 ET

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

BenzingaMay 13 16:20 ET

Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, Vs. Street Est of $9.7M

04:13 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M

MT NewswiresMay 13 16:13 ET